Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations.
Roennow A, Sauvé M, Welling J, Riggs RJ, Kennedy AT, Galetti I, Brown E, Leite C, Gonzalez A, Portales Guiraud AP, Houÿez F, Camp R, Gilbert A, Gahlemann M, Moros L, Luna Flores JL, Schmidt F, Sauter W, Finnern H. Roennow A, et al. Among authors: finnern h. BMJ Open. 2020 Dec 16;10(12):e039473. doi: 10.1136/bmjopen-2020-039473. BMJ Open. 2020. PMID: 33328257 Free PMC article.
What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.
Lester JF, Agulnik J, Akerborg O, Chouaid C, De Geer A, Finnern HW, Herder GJ, Lungershausen J, Mitchell PL, Vansteenkiste J, Ziske C, Goker E. Lester JF, et al. Among authors: finnern hw. Lung Cancer. 2013 Oct;82(1):128-35. doi: 10.1016/j.lungcan.2013.06.023. Epub 2013 Jul 31. Lung Cancer. 2013. PMID: 23910909
Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting.
Chouaid C, Agulnik J, Goker E, Herder GJ, Lester JF, Vansteenkiste J, Finnern HW, Lungershausen J, Eriksson J, Kim K, Mitchell PL. Chouaid C, et al. Among authors: finnern hw. J Thorac Oncol. 2013 Aug;8(8):997-1003. doi: 10.1097/JTO.0b013e318299243b. J Thorac Oncol. 2013. PMID: 23787802 Free article.
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC. Hirsh V, et al. Among authors: finnern hw. J Thorac Oncol. 2013 Feb;8(2):229-37. doi: 10.1097/JTO.0b013e3182773fce. J Thorac Oncol. 2013. PMID: 23328549 Free article. Clinical Trial.
17 results